May 9 |
Q32 Bio GAAP EPS of -$6.33 misses by $4.91
|
May 9 |
Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
|
Apr 11 |
Oppenheimer starts Q32 Bio at outperform, cites lead asset
|
Apr 3 |
Q32 Bio names Lee Kalowski as CFO
|
Apr 3 |
Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer
|
Mar 18 |
Homology Medicines Declares Distribution to Common Stockholders
|
Jan 3 |
Homology Medicines gets non-compliance notice from Nasdaq
|
Jan 3 |
Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency
|
Nov 16 |
Homology Medicines slumps after merger deal with Q32 Bio
|
Nov 16 |
Homology enters reverse merger with Q32 Bio
|